(9ci)-2,4,5-三甲基-1H-苯并咪唑 | 62192-75-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: (9ci)-2,4,5-三甲基-1H-苯并咪唑
• 英文名称: 2,4,5-trimethyl-1H-benzimidazole
• 英文别名: 2,4,5-trimethyl-1(3)H-benzimidazole；2,4,5-Trimethyl-1(3)H-benzimidazol
• CAS: 62192-75-0
• 化学式: C₁₀H₁₂N₂
• mdl: MFCD18807565
• 分子量: 160.219
• InChiKey: MQOSRBNWLNRDOU-UHFFFAOYSA-N

物化性质

• 熔点：
  188-190 °C(Solv: water (7732-18-5); ethanol (64-17-5))
• 沸点：
  367.5±11.0 °C(Predicted)
• 密度：
  1.113±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  3,4-二甲基-O-苯二胺 、 溶剂黄146 在 盐酸 作用下， 生成 (9ci)-2,4,5-三甲基-1H-苯并咪唑
  参考文献：
  名称：

  Beaven et al., Journal of Pharmacy and Pharmacology, 1949, vol. 1, p. 957,968

  摘要：

  DOI：

文献信息

• Cobalamin conjugates for anti-tumor therapy
  申请人：Weinshenker M. Ned

  公开号：US20050054607A1

  公开（公告）日：2005-03-10

  The present invention provides a cobalamin-drug conjugate suitable for the treatment of tumor related diseases. Cobalamin is indirectly covalently bound to an anti-tumor drug via a cleavable linker and one or more optional spacers. Cobalamin is covalently bound to a first spacer or the cleavable linker via the 5′-OH of the cobalamin ribose ring. The drug is bound to a second spacer of the cleavable linker via an existing or added functional group on the drug. After administration, the conjugate forms a complex with transcobalamin (any of its isoforms). The complex then binds to a receptor on a cell membrane and is taken up into the cell. Once in the cell, an intracellular enzyme cleaves the conjugate thereby releasing the drug. Depending upon the structure of the conjugate, a particular class or type of intracellular enzyme affects the cleavage. Due to the high demand for cobalamin in growing cells, tumor cells typically take up a higher percentage of the conjugate than do normal non-growing cells. The conjugate of the invention advantageously provides a reduced systemic toxicity and enhanced efficacy as compared to a corresponding free drug.

  本发明提供了一种适用于治疗肿瘤相关疾病的钴胺素-药物结合物。钴胺素通过可切割的连接剂间接共价结合到抗肿瘤药物上，还可以通过一个或多个可选的间隔物。钴胺素通过其核糖环的5'-OH与第一间隔物或可切割连接剂共价结合。药物通过其现有或添加的功能基团与可切割连接剂的第二间隔物结合。在给药后，结合物与转钴胺素（其任何同工异构体）形成复合物。然后，该复合物结合到细胞膜上的受体并被细胞摄取。一旦进入细胞，细胞内酶将切割结合物，从而释放药物。根据结合物的结构，特定类别或类型的细胞内酶影响切割。由于生长细胞对钴胺素的需求量较高，肿瘤细胞通常摄取结合物的比例高于正常非生长细胞。本发明的结合物与相应的游离药物相比，具有较低的全身毒性和增强的疗效。
• Rapid one-pot preparation of 2-substituted benzimidazoles from 2-nitroanilines using microwave conditions
  作者：David S. VanVliet、Paul Gillespie、Jan J. Scicinski

  DOI：10.1016/j.tetlet.2005.07.130

  日期：2005.9

  A high yielding one-pot procedure for the generation of 2-substituted benzimidazoles directly from 2-nitroanilines by in situ reduction and cyclization using a microwave procedure is described.

  描述了一种高产率的一锅法，该方法通过微波还原法原位还原和环化直接从2-硝基苯胺生成2-取代的苯并咪唑。
• Cobalamin taxane bioconjugates
  申请人：Gebhard John R.

  公开号：US20080233135A1

  公开（公告）日：2008-09-25

  The present invention is directed to methods and compositions including a taxane covalently bonded to the cobalt atom of a cobalamin. The composition can be delivered by any effective route, but is particularly useful as an oral anti-cancer or antiangiogenic compound. The anti-cancer/anti-angiogenic compound can be used in various chemotherapies including anti-angiogenic chemotherapies, alone or in combination with other anti-cancer/anti-angiogenic compounds.

  本发明涉及一种将紫杉醇共价键结合到辅酶B12的钴原子的方法和组合物。该组合物可以通过任何有效途径进行输送，但特别适用于口服抗癌或抗血管生成化合物。抗癌/抗血管生成化合物可用于各种化疗，包括抗血管生成化疗，单独使用或与其他抗癌/抗血管生成化合物结合使用。
• Vitamin directed targeting therapy
  申请人：Russell-Jones Gregory

  公开号：US20050220754A1

  公开（公告）日：2005-10-06

  The invention relates to vitamin-mediated targeting for the delivery of agents and active substances in the therapy of disease. Targeting using vitamins essential for cancer growth are used in complexes for amplified delivery of cytotoxic drugs to tumors and cancer cells, with a concomitant reduction in toxicity to the subject being treated.

  本发明涉及维生素介导的靶向递送治疗疾病的药物和活性物质。使用对癌症生长必需的维生素进行靶向递送，用于复合物中以增强细胞毒性药物对肿瘤和癌细胞的递送，同时减少对治疗对象的毒性。
• Benzimidazole carboxamides as raf kinase inhibitors
  申请人：Buchstaller Hans-Peter

  公开号：US20070093532A1

  公开（公告）日：2007-04-26

  The present invention relates to benzimidazole carboxamides of formula (I), the use of the compounds of formula (I) as inhibitors of as inhibitors of one or more kinases, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. Accordingly, the compound of Formula (I) or a pharmaceutically acceptable salt thereof is administered for the treatment of diseases mediated by one or more kinase phathways, preferably by the raf kinase pathway, especially cancers.

  本发明涉及式（I）的苯并咪唑羧酰胺，以化合物式（I）作为一个或多个激酶的抑制剂，以化合物式（I）制备制药组合物的用途以及治疗方法，包括向患者给予该制药组合物。因此，式（I）的化合物或其药学上可接受的盐被用于治疗由一个或多个激酶途径介导的疾病，优选是通过raf激酶途径，特别是癌症。